New research suggests that a reduction in blood cholesterol might actually prove harmful in kidney cancer patients.
Increasing evidence suggests that alterations in cholesterol and other lipids are associated with the development, progression, and prognosis of various cancers. To assess the situation as it relates to kidney cancer, Tobias Klatte, MD, of the Medical University of Vienna in Austria, and his colleagues analyzed total blood cholesterol levels in 867 patients with renal cell carcinoma before they underwent kidney surgery. The investigators then followed the patients for a median of 52 months
Low blood cholesterol before treatment was associated with more advanced tumor stages and cancer spread during follow-up. Also, patients with high cholesterol had a 43 percent lower risk of dying from their cancer compared with patients with low cholesterol. Finally, including patients’ cholesterol levels with traditional risk factors increased the accuracy of prognoses.
Read the press release here: http://bit.ly/1v5pnPt
Source: Wiley
Oncology Onward: A Conversation With Penn Medicine's Dr Justin Bekelman
December 19th 2023Justin Bekelman, MD, director of the Penn Center for Cancer Care Innovation, sat with our hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, for our final episode of 2023 to discuss the importance of collaboration between academic medicine and community oncology and testing innovative cancer care delivery in these settings.
Listen
FDA Approves Tislelizumab for Advanced or Metastatic ESCC After Chemotherapy
March 15th 2024The FDA has approved tislelizumab-jsgr (Tevimbra) for single-agent use in adult patients with unresectable or metastatic esophageal squamous cell carcinoma following prior systemic chemotherapy that did not include a PD-1/PD-L1 inhibitor.
Read More